Last Updated: November 16, 2026

Details for Patent: 8,022,054

« Back to Dashboard


Which drugs does patent 8,022,054 protect, and when does it expire?

Patent 8,022,054 protects ZTALMY and is included in one NDA.

This patent has twenty-four patent family members in fourteen countries.

Summary for Patent: 8,022,054
Title:Liquid ganaxolone formulations and methods for the making and use thereof
Abstract:In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
Inventor(s):Kenneth Shaw, Mingbao Zhang
Assignee: Immedica Pharma US Inc
Application Number:US11/605,700
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,022,054
Patent Claim Types:
see list of patent claims
Formulation; Compound;
Patent landscape, scope, and claims:

United States Patent 8,022,054: Ganaxolone Aqueous Dispersion Claims and Patent Landscape

U.S. Patent No. 8,022,054 claims a stabilized aqueous dispersion of nanoparticulate ganaxolone. The central legal requirements are a hydrophilic polymer, wetting agent, qualifying low-molecular-weight aromatic complexing agent, dual-preservative system, and ganaxolone particles with a volume-weighted median diameter of 50 to 500 nm. The claims also cover particle-growth control, gastrointestinal dispersion behavior, storage stability, composition ranges, pharmacokinetic performance, and a 50 mg/mL formulation.

The broadest claim is composition claim 1. The dependent claims progressively narrow the formulation through excipient identity, concentration, particle size, stability testing, processing endpoint, preservative selection, and clinical pharmacokinetic outcomes. The patent is therefore most relevant to liquid oral ganaxolone products using a nanoparticle suspension rather than to ganaxolone generally.

What does U.S. Patent 8,022,054 protect?

Claim 1 requires all of the following elements:

Required element Claim 1 limitation
Active ingredient Ganaxolone
Dosage form Aqueous dispersion
Particle architecture Stabilized ganaxolone particles
Polymer Hydrophilic polymer
Wetting agent Present in the dispersion
Complexing agent Effective amount that stabilizes particle growth after an initial growth phase and endpoint
Complexing-agent chemistry Small organic molecule with molecular weight below 550 and a phenol, aromatic ester, or aromatic acid moiety
Particle size D50 of approximately 50 to 500 nm
Complexing-agent concentration Approximately 0.05% to 5% w/w based on particle weight
Microbial protection At least two preservatives in an amount sufficient to inhibit microbial growth

The claim is cumulative. A formulation that contains ganaxolone, a polymer, and a wetting agent but lacks the claimed complexing agent or dual-preservative system would not satisfy claim 1 as written.

The claim also uses functional language. The complexing agent must stabilize particle growth after an initial growth period and endpoint. The formulation must contain the agent in an amount that performs that function. Particle size alone is insufficient.

How broad is the independent composition claim?

Claim 1 is chemically broad but formulation-specific.

The complexing-agent definition includes at least three structural classes:

  1. Phenol-containing molecules.
  2. Aromatic esters.
  3. Aromatic acids.

The claim imposes a molecular-weight ceiling of less than 550. The dependent claims identify methylparaben, propylparaben, benzoic acid, pharmaceutically acceptable salts, mixtures, and methyl anthranilate as examples.

The claim does not require a particular hydrophilic polymer, wetting agent, preservative, salt, sweetener, or ganaxolone concentration. Those limitations appear in dependent claims. A competing product could therefore avoid many dependent claims while remaining within claim 1 if it retains the required core elements.

The most important breadth issue is the relationship between the particle-stabilization function and the claimed excipient classes. A formulation may contain a qualifying aromatic compound, but infringement would likely depend on whether the compound actually performs the claimed particle-growth stabilization function at the claimed concentration.

What formulations are protected by the dependent claims?

Polymer and wetting-agent limitations

Claims 2 and 3 define broad concentration ranges:

Component Claimed range
Hydrophilic polymer 3% to 50% w/w of dispersion
Wetting agent 0.01% to 10% w/w of dispersion
Ganaxolone under claim 12 10% to 80% w/w of dispersion
Ganaxolone under claim 18 Approximately 5% w/w
Ionic dispersion modulator 1% to 50% w/w of dispersion

Claims 13 to 17 identify cellulosic and vinyl polymers. The specified examples include cellulose ethers, hydroxypropylmethylcellulose, vinyl pyrrolidone/vinyl acetate copolymer S630, and polyvinyl alcohol.

Claims 19 identifies sodium lauryl sulfate, pharmaceutically acceptable docusate salts, and mixtures as wetting agents.

Particle-size limitations

The principal particle-size range is 50 to 500 nm under claim 1. The dependent ranges narrow the target:

Claim Particle-size requirement
1 D50 approximately 50 to 500 nm
9 D50 approximately 100 to 450 nm
10 D50 approximately 100 to 350 nm
37 D50 below approximately 250 nm
38 D50 below approximately 150 nm

These claims concern volume-weighted median diameter, not merely a mean or number-weighted average. Measurement method, sample preparation, dispersion conditions, and instrument settings could become material in an infringement or validity dispute.

Preservative limitations

Claim 1 requires at least two preservatives. Claim 51 lists:

  • Potassium sorbate
  • Methylparaben
  • Propylparaben
  • Benzoic acid
  • Butylparaben
  • Ethyl alcohol
  • Benzyl alcohol
  • Phenol
  • Benzalkonium chloride
  • Mixtures of these materials

The claim language appears to permit any combination of at least two qualifying preservatives, subject to the requirement that the amount be sufficient to inhibit microbial growth. A formulation using one preservative, or a nonlisted preservative combination, would require separate analysis under the broader wording of claim 1.

When does the patent claim particle-growth stability?

Claims 4 to 8 require that D50 change by no more than approximately 15% after storage at room temperature for:

  • 10 days
  • 20 days
  • 40 days
  • 60 days
  • 80 days

Claims 27 and 28 add accelerated thermal stability:

  • No more than approximately 15% D50 change after 20 minutes in a 100°C oil bath.
  • No more than approximately 15% D50 change after four hours in a 100°C oil bath.

Claim 29 addresses simulated gastric and intestinal conditions. It requires a D50 increase of no more than approximately 150% after one hour at 36°C to 38°C in SGF or SIF at a ganaxolone concentration of 0.5 to 1 mg/mL.

These limitations create evidentiary issues. A product may have the same nominal composition but fall outside a stability claim if its measured D50 changes beyond the specified threshold. Conversely, a stability claim may be difficult to enforce without a defined baseline, analytical protocol, storage humidity, vial configuration, and particle-size methodology.

What endpoint and complexing agents are protected?

Claims 32 to 36 tie the complexing agent to the particle-growth endpoint:

Claim Limitation
32 Endpoint approximately 5 to 25 days
33 Endpoint approximately 7 to 14 days
34 Endpoint approximately 5 to 7 days
35 Methylparaben with endpoint approximately 5 to 7 days
36 Benzoic acid with endpoint up to approximately three weeks

Claim 35 is particularly narrow because it combines a specific complexing agent with a defined endpoint. Claim 36 does the same for benzoic acid.

The patent’s technical concept is not simply adding a preservative to an oral suspension. It is using selected aromatic small molecules to control post-milling or post-dispersion particle growth after an initial growth phase. That functional distinction is central to both infringement analysis and validity analysis.

What pharmacokinetic outcomes are claimed?

Claims 44 to 50 protect formulations by pharmacokinetic performance in adult subjects. The relevant limitations include:

Claim Pharmacokinetic requirement
44 Fed-to-fasted AUC ratio approximately 1.5:1 to 5:1
45 Fed-to-fasted Cmax ratio approximately 2:1 to 7:1
46 Fasted AUC0-24 approximately 100 to 375 ng·h/mL after 200 to 500 mg
47 Fasted Cmax approximately 25 to 70 ng/mL after 200 to 500 mg
48 Fed AUC0-48 approximately 400 to 1,200 ng·h/mL after 200 to 500 mg
49 Fed Cmax approximately 60 to 250 ng/mL after 200 to 500 mg
50 Steady-state Cmax/Cmin no greater than approximately 4:1

These are product-by-process-adjacent limitations expressed through clinical performance. They may create a substantial enforcement burden because infringement would require demonstrating that the accused formulation produces the claimed pharmacokinetic result under comparable dose, fed-state, fasted-state, population, sampling, and statistical conditions.

The claims do not necessarily require a particular commercial label or indication. A formulation used for a different indication could still implicate the composition claims if the structural and functional requirements are met.

What is the commercial relevance to ZTALMY?

Ganaxolone is marketed in the United States as ZTALMY, an oral suspension approved by the FDA for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients two years of age and older. The product is an aqueous oral suspension containing 50 mg/mL ganaxolone, making claims 43 and 51 commercially relevant to the marketed dosage form.[2]

The FDA-approved product contains excipients that should be compared against the patent claim limitations, including the identity and concentration of the polymer, wetting agent, preservatives, sweetener, and any aromatic complexing agent. The presence of a 50 mg/mL concentration alone does not establish coverage because claim 43 depends on the broader formulation requirements of claim 1.

The principal product-level risk questions are:

  1. Whether the commercial suspension has ganaxolone particles within the claimed D50 range.
  2. Whether it uses a qualifying aromatic complexing agent.
  3. Whether the agent is present at 0.05% to 5% w/w based on particle weight.
  4. Whether the product contains at least two preservatives.
  5. Whether the agent stabilizes particle growth after the claimed endpoint.
  6. Whether the product satisfies any dependent pharmacokinetic or stability limitations.

What is the Orange Book status of U.S. Patent 8,022,054?

FDA Orange Book coverage must be determined from the current Approved Drug Products with Therapeutic Equivalence Evaluations database and the relevant ZTALMY listing. A patent’s existence does not establish that it is listed for a specific approved product.

For Hatch-Waxman purposes, an Orange Book-listed patent may support a Paragraph IV certification by an abbreviated new drug application applicant. A patent that is not listed generally does not create the same statutory notice and 30-month-stay framework, although it may remain enforceable in separate patent litigation.

The patent’s claims are composition claims rather than only method-of-use claims. If listed against an approved ganaxolone oral suspension, it would be more significant to generic applicants than a patent limited to an indication or dosing method. The decisive commercial issues are the current listing status, listed expiration date, any pediatric exclusivity adjustment, and whether the patent remains enforceable.

When does U.S. Patent 8,022,054 lose exclusivity?

U.S. patent term generally runs for 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and applicable transitional rules.[3] The issue date, September 20, 2011, does not by itself determine expiration.

The relevant term analysis is:

Event Legal significance
Earliest effective nonprovisional filing Primary term-start date
Patent issuance Confers issued patent rights but does not ordinarily start the 20-year term
Patent-term adjustment May extend the term for qualifying USPTO delay
Patent-term extension May extend the term for regulatory review under 35 U.S.C. § 156
Pediatric exclusivity May add six months to listed patent and exclusivity periods
Terminal disclaimer May limit expiration to an earlier patent’s expiration date

A definitive expiration date requires the official USPTO continuity and Patent Center records, the front-page patent-term-adjustment calculation, and any terminal disclaimer or regulatory extension record. The supplied claim text alone does not establish those dates.

Which companies are challenging the patent?

No Paragraph IV challenger, ANDA litigation, settlement agreement, or district-court case can be identified from the claim text. A reliable challenger analysis requires a current search of:

  • FDA Orange Book patent certifications;
  • FDA Paragraph IV notice records;
  • PACER and district-court dockets;
  • Delaware, New Jersey, and other pharmaceutical-litigation venues;
  • PTAB inter partes review and post-grant review records;
  • USPTO assignment and maintenance-fee records.

The absence of a challenger in the supplied material should not be treated as evidence that no challenge exists.

How strong is the patent estate?

The patent has meaningful technical specificity but mixed enforcement breadth.

Strengths

  • Claim 1 combines composition, particle-size, excipient, and stability requirements.
  • The 50 to 500 nm range covers a commercially plausible nanoparticulate suspension.
  • Claims 11, 35, 36, and 39 to 42 identify practical aromatic complexing agents.
  • Claims 4 to 8 and 27 to 29 provide measurable stability parameters.
  • Claims 43 to 50 connect the formulation to the 50 mg/mL product and pharmacokinetic performance.

Vulnerabilities

  • The claim requires proof of a functional particle-growth stabilization effect.
  • “Initial particle growth” and “endpoint” may require specification-based construction.
  • D50 measurements can vary with analytical method and sample preparation.
  • The dual-preservative limitation may exclude otherwise similar formulations.
  • The pharmacokinetic claims depend on human-study conditions and may be difficult to prove.
  • The breadth of the aromatic complexing-agent genus may invite written-description, enablement, or obviousness challenges.
  • Several dependent claims create potential clarity and dependency issues. Claim 17, for example, identifies polyvinyl alcohol after depending from claim 16, which identifies vinyl pyrrolidone/vinyl acetate copolymer S630. The scope may depend on how the claim dependency and polymer alternatives are construed.

How does this patent compare with later ganaxolone patents?

U.S. Patent 8,022,054 should be separated from later patents directed to:

  • Specific ZTALMY compositions;
  • Dosing regimens;
  • Particular therapeutic indications;
  • Manufacturing processes;
  • Particle-size-control methods;
  • Formulation excipient combinations;
  • Crystalline or amorphous ganaxolone forms;
  • Pediatric administration and labeling.

An applicant designing around this patent could target a formulation that changes one or more required elements, such as:

  • A nonaromatic complexing or stabilizing agent;
  • A particle size outside the 50 to 500 nm range;
  • A single preservative system;
  • A different polymer or wetting agent;
  • A formulation without the claimed post-growth endpoint;
  • A solid dosage form instead of an aqueous dispersion.

Design-around success would depend on the doctrine of equivalents, prosecution-history estoppel, and the exact scope of any continuation or related patent family.

What manufacturing and geographic barriers remain?

The patent is a U.S. right. Corresponding foreign applications, national-phase patents, continuations, and divisionals must be reviewed separately for Europe, Japan, Canada, Australia, and other commercial markets.

Manufacturing barriers may arise from the need to reproduce:

  • Nanoparticle size within a controlled D50 range;
  • The initial particle-growth phase;
  • The claimed stabilization endpoint;
  • Uniform preservative distribution;
  • Microbial-control performance;
  • Stability under room-temperature and thermal stress;
  • Gastric and intestinal dispersion behavior.

A process can be commercially difficult to reproduce without being literally claimed. Conversely, a manufacturing process may infringe a related process patent even if the resulting formulation avoids claim 1 of this patent.

Key Takeaways

  • Claim 1 is the central protection and requires a stabilized aqueous ganaxolone nanoparticle dispersion.
  • The essential combination is ganaxolone, hydrophilic polymer, wetting agent, qualifying aromatic complexing agent, 50 to 500 nm D50, and at least two preservatives.
  • Claims 11, 35, 36, and 39 to 42 make methylparaben, propylparaben, benzoic acid, and methyl anthranilate commercially important.
  • The patent specifically targets particle-growth stabilization after an initial growth period.
  • Claims 4 to 8, 27 to 29, and 32 to 38 impose measurable stability, endpoint, gastrointestinal, and particle-size requirements.
  • Claims 43 to 50 connect the formulation to a 50 mg/mL product and specified pharmacokinetic outcomes.
  • ZTALMY’s 50 mg/mL aqueous oral suspension makes the patent commercially relevant, but concentration alone does not establish infringement.
  • Current Orange Book listing, patent expiration, Paragraph IV activity, litigation, and settlement status cannot be determined from the supplied claims.
  • Patent-term analysis must use the earliest effective nonprovisional filing date, PTA, PTE, terminal disclaimers, and pediatric exclusivity records.
  • The strongest design-around paths involve changing the complexing agent, preservative system, particle-size range, or dispersion architecture.

FAQs About U.S. Patent 8,022,054

Does U.S. Patent 8,022,054 cover all ganaxolone products?

No. Its claims are directed to a specific aqueous nanoparticulate dispersion architecture and require multiple excipient, particle-size, stabilization, and preservation limitations.

Does a 50 mg/mL ganaxolone suspension automatically infringe?

No. Claim 43 depends on claim 1. The product must also satisfy the claim 1 requirements, including particle size, complexing agent, particle-growth stabilization, hydrophilic polymer, wetting agent, and dual-preservative system.

Can a generic avoid the patent by using a different preservative?

Potentially, if the alternative formulation does not contain at least two preservatives within the scope of claim 1 and does not meet the remaining claim elements. The complete formulation and equivalents analysis controls.

Are the pharmacokinetic claims likely to be important in ANDA litigation?

They can be relevant, but they may be harder to prove than composition claims because infringement depends on clinical performance under defined fed, fasted, dose, sampling, and steady-state conditions.

Does patent expiration eliminate FDA exclusivity?

No. Patent term and FDA regulatory exclusivity are separate rights. NCE, orphan-drug, pediatric, and other exclusivity periods can continue after a patent expires, while a patent can expire before regulatory exclusivity ends.

References

  1. United States Patent and Trademark Office. (2011). U.S. Patent No. 8,022,054.
  2. U.S. Food and Drug Administration. (2022). ZTALMY (ganaxolone) oral suspension prescribing information.
  3. Patent Act, 35 U.S.C. §§ 154, 156, 271, 355.
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,022,054

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Immedica Pharma ZTALMY ganaxolone SUSPENSION;ORAL 215904-001 Jun 1, 2022 RX Yes Yes 8,022,054 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,022,054

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1959966 ⤷  Start Trial 122024000005 Germany ⤷  Start Trial
European Patent Office 1959966 ⤷  Start Trial C202430002 Spain ⤷  Start Trial
African Regional IP Organization (ARIPO) 3071 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.